Trial · NCT00227877
Screening and Brief Advice to Reduce Teen Substance Use
NCT00227877, Not applicable, Completed, Boston Children's Hospital; results first posted 2018-09-21
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Screening and Brief Advice to Reduce Teen Substance Use. Trials, record NCT00227877. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00227877
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Screening and Brief Advice to Reduce Teen Substance Use
- NCT number
- NCT00227877
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 2,695 participants, actual
- Lead sponsor
- Boston Children's Hospital
- Conditions
- Substance Related Disorders
- Interventions
- cSBA - New England, USA, cSBA - Prague, CZR
- First posted
- 2005-09-28
- Last updated
- 2019-08-14
- Results first posted
- 2018-09-21
- Limitations and caveats
Use of non-randomized, asynchronous study design may have confounded results; 2 NE groups not equivalent in baseline substance use (but controlled for in analysis); self-report and interview-collected data prone to recall and social desirability bias
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Past-90-day Substance Use at 3 Months Among Baseline Substance Users - New England, USA | Past-90-days at 3 months post-baseline | Among the 12-18 year old primary care patients who reported past-12-month drug or alcohol use at baseline in New England, USA, this analysis reports the number who subsequently reported past-90-day drug or alcohol use at the 3 months post-baseline assessment. |
| Primary | Past-90-day Substance Use at 3 Months Among Baseline Substance Non-Users, New England, USA | Past-90-days at 3 months post-baseline | Among the 12-18 year old primary care patients who did NOT report past-12-month drug or alcohol use at baseline in New England, USA, this analysis reports the number who subsequently reported past-90-day drug or alcohol use at the 3 months post-baseline assessment. |
| Primary | Past-12-month Substance Use at 12 Months Among Baseline Substance Users, New England, USA | Past-12-months at 12 months post-baseline | Of those participants who reported past-12-month drug or alcohol use at baseline,the number reporting past-90-day drug or alcohol use at 12 months post-baseline assessment in New England, USA |
| Primary | Past-12-month Substance Use at 12 Months, Baseline Substance Non-Users, New England, USA | Past-12-months at 12 months post-baseline | Of those participants who reported NO past-12-month drug or alcohol use at baseline,the number reporting past-90-day drug or alcohol use at 12 months post-baseline assessment in New England, USA |
| Primary | Past-90-day Substance Use at 3 Months Among Baseline Substance Users - Prague, CZR | Past-90-days at 3 months post-baseline | Of those participants who reported past-12-month drug or alcohol use at baseline,the number reporting past-90-day drug or alcohol use at 3 months post-baseline assessment in Prague, Czech Republic |
| Primary | Past-90-day Substance Use at 3 Months Among Baseline Substance Non-Users - Prague, CZR | Past-90-days at 3 months post-baseline | Of those participants who reported NO past-12-month drug or alcohol use at baseline,the number reporting past-90-day drug or alcohol use at 3 months post-baseline assessment in Prague, Czech Republic |
| Primary | Past-12-Month Substance Use at 12 Months Among Baseline Substance Users - Prague, CZR | Past-12-months at 12 months post-baseline | Of those participants who reported past-12-month drug or alcohol use at baseline,the number reporting past-12-month drug or alcohol use at 12 months post-baseline assessment in Prague, Czech Republic |
| Primary | Past-12-Month Substance Use at 12 Months Among Baseline Substance Non-Users - Prague, CZR | Past-12-months at 12 months post-baseline | Of those participants who reported past-12-month drug or alcohol use at baseline,the number reporting past-12-month drug or alcohol use at 12 months post-baseline assessment in Prague, Czech Republic |
| Secondary | Any Risky Riding or Driving at 3 Months - New England, USA | Past-90-days at 3 months post-baseline | Any past-90-day self-reported Riding with a driver who had used alcohol or other drugs or Driving after having used alcohol or other drugs at 3 months post-baseline assessment - New England |
| Secondary | Any Risky Riding or Driving at 12 Months - New England, USA | Past-90-days at 12 months post-baseline | Any past-90-day self-reported Riding with a driver who had used alcohol or other drugs or Driving after having used alcohol or other drugs at 12 months post-baseline assessment - New England |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Past-90-day Substance Use at 3 Months Among Baseline Substance Users - New England, USA | Past-90-days at 3 months post-baseline | 12-18 year old primary care patients who report past-12-month drug or alcohol use at baseline in New England, USA | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Past-90-day Substance Use at 3 Months Among Baseline Substance Non-Users, New England, USA | Past-90-days at 3 months post-baseline | 12-18 year old primary care patients who did not report past-12-month drug or alcohol use at baseline in New England, USA | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Past-12-month Substance Use at 12 Months Among Baseline Substance Users, New England, USA | Past-12-months at 12 months post-baseline | 12-18 year old primary care patients who reported past-12-month drug or alcohol use at baseline in New England, USA | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Past-12-month Substance Use at 12 Months, Baseline Substance Non-Users, New England, USA | Past-12-months at 12 months post-baseline | 12-18 year old primary care patients who did not report past-12-month drug or alcohol use at baseline in New England, USA | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Past-90-day Substance Use at 3 Months Among Baseline Substance Users - Prague, CZR | Past-90-days at 3 months post-baseline | 12-18 year old primary care patients who reported past-12-month drug or alcohol use at baseline in Prague, CZR | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Past-90-day Substance Use at 3 Months Among Baseline Substance Non-Users - Prague, CZR | Past-90-days at 3 months post-baseline | 12-18 year old primary care patients who did not report past-12-month drug or alcohol use at baseline in Prague, CZR | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Past-12-Month Substance Use at 12 Months Among Baseline Substance Users - Prague, CZR | Past-12-months at 12 months post-baseline | 12-18 year old primary care patients who reported past-12-month drug or alcohol use at baseline in Prague, CZR | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Past-12-Month Substance Use at 12 Months Among Baseline Substance Non-Users - Prague, CZR | Past-12-months at 12 months post-baseline | 12-18 year old primary care patients who did not report past-12-month drug or alcohol use at baseline in Prague, CZR | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Any Risky Riding or Driving at 3 Months - New England, USA | Past-90-days at 3 months post-baseline | 12-18 year old primary care patients in New England, USA | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Any Risky Riding or Driving at 12 Months - New England, USA | Past-90-days at 12 months post-baseline | 12-18 year old primary care patients in New England, USA | Participants | COUNT_OF_PARTICIPANTS |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 outcomesResults by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Past-90-day Substance Use at 3 Months Among Baseline Substance Users - New England, USA | Control - New England, USA | 162 | Participants | ||
| Past-90-day Substance Use at 3 Months Among Baseline Substance Users - New England, USA | Computer Screen & Brief Physician Advice - New England, USA | 121 | Participants | ||
| Past-90-day Substance Use at 3 Months Among Baseline Substance Non-Users, New England, USA | Control - New England, USA | 24 | Participants | ||
| Past-90-day Substance Use at 3 Months Among Baseline Substance Non-Users, New England, USA | cSBA - New England, USA | 15 | Participants | ||
| Past-12-month Substance Use at 12 Months Among Baseline Substance Users, New England, USA | Control - New England, USA | 214 | Participants | ||
| Past-12-month Substance Use at 12 Months Among Baseline Substance Users, New England, USA | Computer Screen & Brief Physician Advice - New England, USA | 172 | Participants | ||
| Past-12-month Substance Use at 12 Months, Baseline Substance Non-Users, New England, USA | Control - New England, USA | 83 | Participants | ||
| Past-12-month Substance Use at 12 Months, Baseline Substance Non-Users, New England, USA | cSBA - New England, USA | 73 | Participants | ||
| Past-90-day Substance Use at 3 Months Among Baseline Substance Users - Prague, CZR | Control - Prague, CZR | 118 | Participants | ||
| Past-90-day Substance Use at 3 Months Among Baseline Substance Users - Prague, CZR | cSBA - Prague, CZR | 114 | Participants |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 results by groupParticipant flow48
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Pre-visit Assessment | STARTED | Control - New England | 1,075 | |
| Pre-visit Assessment | STARTED | cSBA - New England | 1,031 | |
| Pre-visit Assessment | STARTED | Control - Czech Republic | 297 | |
| Pre-visit Assessment | STARTED | cSBA - Czech Republic | 292 | |
| Pre-visit Assessment | COMPLETED | Control - New England | 1,068 | |
| Pre-visit Assessment | COMPLETED | cSBA - New England | 1,028 | |
| Pre-visit Assessment | COMPLETED | Control - Czech Republic | 297 | |
| Pre-visit Assessment | COMPLETED | cSBA - Czech Republic | 292 | |
| Pre-visit Assessment | NOT COMPLETED | Control - New England | 7 | |
| Pre-visit Assessment | NOT COMPLETED | cSBA - New England | 3 |
1 to 10 of 48Source ClinicalTrials.gov
See all 48 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Control - New England | ||
| Total, all-cause mortality | Computer Screen & Brief Physician Advice - New England | ||
| Total, all-cause mortality | Control - Czech Republic | ||
| Total, all-cause mortality | Computer Screen & Brief Physician Advice - Czech Republic | ||
| Total, other adverse events | Control - New England | 0 | 1,068 |
| Total, other adverse events | Computer Screen & Brief Physician Advice - New England | 0 | 1,028 |
| Total, other adverse events | Control - Czech Republic | 0 | 297 |
| Total, other adverse events | Computer Screen & Brief Physician Advice - Czech Republic | 0 | 292 |
| Total, serious adverse events | Control - New England | 0 | 1,068 |
| Total, serious adverse events | Computer Screen & Brief Physician Advice - New England | 0 | 1,028 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers13
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons12
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| cSBA - Prague, CZR vs Control - Prague, CZR: Any Risky Riding or Driving at 3 Months - Prague, CZR | Trial comparisons |
| Computer Screen & Brief Physician Advice - New England, USA vs Control - New England, USA: Past-12-month Substance Use at 12 Months Among Baseline Substance Users, New England, USA | Trial comparisons |
| cSBA - Prague, CZR vs Control - Prague, CZR: Any Risky Riding or Driving at 12 Months - Prague, CZR | Trial comparisons |
| cSBA - Prague, CZR vs Control - Prague, CZR: Past-90-day Substance Use at 3 Months Among Baseline Substance Non-Users - Prague, CZR | Trial comparisons |
| cSBA - Prague, CZR vs Control - Prague, CZR: Past-12-Month Substance Use at 12 Months Among Baseline Substance Non-Users - Prague, CZR | Trial comparisons |
| cSBA - Prague, CZR vs Control - Prague, CZR: Past-90-day Substance Use at 3 Months Among Baseline Substance Users - Prague, CZR | Trial comparisons |
| cSBA - New England, USA vs Control - New England, USA: Past-12-month Substance Use at 12 Months, Baseline Substance Non-Users, New England, USA | Trial comparisons |
| cSBA - Prague, CZR vs Control - Prague, CZR: Past-12-Month Substance Use at 12 Months Among Baseline Substance Users - Prague, CZR | Trial comparisons |
| Computer Screen & Brief Physician Advice - New England, USA vs Control - New England, USA: Past-90-day Substance Use at 3 Months Among Baseline Substance Users - New England, USA | Trial comparisons |
| cSBA - New England, USA vs Control - New England, USA: Any Risky Riding or Driving at 12 Months - New England, USA | Trial comparisons |
1 to 10 of 12
See all 12 trial comparisonsTests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00227877
GET https://conductscience.org/api/trials/v1/NCT00227877/results?page=2